Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
ESC Heart Fail. 2023 Apr;10(2):1347-1357. doi: 10.1002/ehf2.14301. Epub 2023 Feb 2.
The aim was to describe the prevalence, characteristics, and outcome of patients with acute myocardial infarction (MI) developing left ventricular (LV) systolic dysfunction or pulmonary congestion by applying different criteria to define the population.
In patients with MI included in the Swedish web-system for enhancement and development of evidence-based care in heart disease (SWEDEHEART) registry, four different sets of criteria were applied, creating four not mutually exclusive subsets of patients: patients with MI and ejection fraction (EF) < 50% and/or pulmonary congestion (subset 1); EF < 40% and/or pulmonary congestion (subset 2); EF < 40% and/or pulmonary congestion and at least one high-risk feature (subset 3, PARADISE-MI like); and EF < 50% and no diabetes mellitus (subset 4, DAPA-MI like). Subsets 1, 2, 3, and 4 constituted 31.6%, 15.0%, 12.8%, and 22.8% of all patients with MI (n = 87 177), respectively. The age and prevalence of different co-morbidities varied between subsets. For median age, 70 to 77, for diabetes mellitus, 22 to 33%; for chronic kidney disease, 22 to 38%, for prior MI, 17 to 21%, for atrial fibrillation, 7 to 14%, and for ST-elevations, 38 to 50%. The cumulative incidence of death or heart failure hospitalization at 3 years was 17.4% (95% CI: 17.1-17.7%) in all MIs; 26.9% (26.3-27.4%) in subset 1; 37.6% (36.7-38.5%) in subset 2; 41.8% (40.7-42.8%) in subset 3; and 22.6% (22.0-23.2%) in subset 4.
Depending on the definition, LV systolic dysfunction or pulmonary congestion is present in 13-32% of all patients with MI and is associated with a two to three times higher risk of subsequent death or HF admission. There is a need to optimize management and improve outcomes for this high-risk population.
本研究旨在通过应用不同标准来定义人群,描述急性心肌梗死(MI)患者中出现左心室(LV)收缩功能障碍或肺充血的患病率、特征和转归。
在纳入瑞典心脏病增强和发展循证治疗网络系统(SWEDEHEART)注册研究的 MI 患者中,应用了 4 种不同的标准,由此产生了 4 个非相互排斥的患者亚组:MI 伴射血分数(EF)<50%和/或肺充血(亚组 1);EF<40%和/或肺充血(亚组 2);EF<40%和/或肺充血和至少 1 项高危特征(PARADISE-MI 样亚组 3);以及 EF<50%且无糖尿病(DAPA-MI 样亚组 4)。亚组 1、2、3 和 4 分别占所有 MI 患者(n=87177)的 31.6%、15.0%、12.8%和 22.8%。各亚组间年龄和不同合并症的患病率存在差异。中位年龄分别为 70 岁至 77 岁、糖尿病 22%至 33%、慢性肾脏病 22%至 38%、既往 MI 17%至 21%、心房颤动 7%至 14%、ST 段抬高 38%至 50%。所有 MI 患者 3 年时死亡或心力衰竭住院的累积发生率为 17.4%(95%CI:17.1%-17.7%);亚组 1 为 26.9%(26.3%-27.4%);亚组 2 为 37.6%(36.7%-38.5%);亚组 3 为 41.8%(40.7%-42.8%);亚组 4 为 22.6%(22.0%-23.2%)。
根据定义,LV 收缩功能障碍或肺充血在所有 MI 患者中的占比为 13%-32%,与随后死亡或 HF 入院的风险增加 2 至 3 倍相关。需要优化该高危人群的管理并改善其结局。